2024 U.K. Hemostasis Analyzers and Reagents--Chromogenic, Immunodiagnostic, Molecular Coagulation Test Volume and Sales Segment Forecasts for Hospitals, Commercial/Private Labs and POC Locations--2023 Competitive Shares and Growth Strategies, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

March 2024 | | ID: 2E2326C3CF3FEN
Venture Planning Group

Abstracts

SummaryThis comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market during the next five years.The report is available by section, and can be customized to specific information needs and budget.The report explores business and technological trends in the UK coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.Coagulation TestsActivated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2%li%Antiplasmin, Antithrombin III, Bleeding Time, D%li%Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre%li%Kallikrein Factor Activation, Heparin/Anti%li%Factor Xa, Heparin%li%Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's, Factor Fav/Ag, and others.Sales and Market Share Analysis%li% Sales and market shares of major instrument and reagent suppliers.Competitive Assessments%li% Extensive strategic profiles of major suppliers and emerging market entrants.Market Segmentation Analysis%li% Comprehensive market segmentation analysis, including:Hospitals, Commercial/Private Laboratories%li% Test volume forecasts for over 40 major procedures by market segment.Current and Emerging Products%li% Review of established and emerging procedures.%li% Comparison of automated and semi%li%automated analyzers from Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.Technology Review%li% Analysis of current and emerging technologies and their potential market applications.%li% Comprehensive lists of companies developing or marketing new technologies and products by test.Strategic Recommendations%li% Product development and business expansion opportunities with significant market appeal.%li% Ideal product models with tentative prices and operating characteristics.%li% Alternative market penetration strategies for instrument and reagent suppliers.%li% Potential market entry barriers and risks.

Contents

I. Introduction
II. Worldwide Market and Technology Overview
A. Major Routine and Special Coagulation Tests

1. INTRODUCTION

2. ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

3. ALPHA-2 ANTIPLASMIN

4. ANTITHROMBIN III

5. BLEEDING TIME

6. D-DIMER

7. ETHANOL FLOCCULATION TEST

8. EUGLOBULIN LYSIS

9. FACTOR ASSAYS

a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII

10. FIBRIN DEGRADATION PRODUCTS

11. FIBRINOGEN

12. HEPARIN

13. HIRUDIN

14. HYPERCOAGULABILITY AND THROMBOSIS

15. LIPOPROTEIN A

16. PLASMIN

17. PLASMINOGEN

18. PLASMINOGEN ACTIVATOR INHIBITOR (PAI)

19. PLATELET FUNCTION TESTS

20. PLATELET AGGREGATION

21. PROTEINS C AND S

22. PROTHROMBIN FRAGMENT 1.2

23. PROTHROMBIN TIME (PT)

24. REPTILASE TIME

25. THROMBIN TIME

26. TISSUE-TYPE PLASMINOGEN ACTIVATOR (T-PA)

27. VON WILLEBRAND'S FACTOR

B. Instrumentation Review
C. Major in Vitro Diagnostic Technologies and Their
Potential Applications

1. CHROMOGENIC SUBSTRATES

2. MONOCLONAL AND POLYCLONAL ANTIBODIES

3. IMMUNOASSAYS

4. MOLECULAR DIAGNOSTICS

5. MICROCOMPUTERS

6. AUTOMATION

7. ROBOTICS

8. ARTIFICIAL INTELLIGENCE

9. DRY CHEMISTRY

10. BIOSENSORS

III. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Instrument
and Reagent Suppliers’ Sales and Market Shares
IV. Major Product Development Opportunities
V. Design Criteria For Decentralized Testing Products
VI. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets

1. MARKETING APPROACHES

2. PRODUCT COMPLEXITY

3. CUSTOMER PREFERENCE

4. ESTABLISHED SUPPLIERS

5. EMERGING SUPPLIERS

6. MAJOR TYPES OF DISTRIBUTORS

7. MARKET SEGMENTATION

VII. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VIII. Competitive Assessments
The report provides strategic assessments of over 20 leading coagulation
market players and start-up companies with innovative technologies and
products, including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratories
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others